“Rapid identification of carbapenemases and in vitro synergy testing of ceftazidime-avibactam with aztreonam in extensively drug-resistant Gram-negative pathogens: Establishing the realm of promise”

IF 1.4 4区医学 Q4 IMMUNOLOGY

Indian Journal of Medical Microbiology Pub Date : 2025-04-09 DOI:10.1016/j.ijmmb.2025.100834

Debasish Biswal , Maitrayee Narayan , Sarita Mohapatra , Hitender Gautam , Benu Dhawan , Bimal Kumar Das , Virinder Kumar Bansal , Naveet Wig , Seema Sood

引用次数: 0

Abstract

This study evaluated the effectiveness of ceftazidime-avibactam (CZA) alone and in combination with aztreonam (ATM) against 50 extensively drug-resistant (XDR) Gram-negative bacteria (GNB) isolates using disk stacking method. New Delhi metallo-beta-lactamase (NDM) was the predominant carbapenemase, detected in 50% of isolates showing synergy. The CZA-ATM combination demonstrated synergy in 40% of isolates, with 75% of patients receiving this combination achieving microbiological clearance. This simple, rapid synergy testing method can guide effective therapeutic decisions in resource-limited settings.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Journal of Medical Microbiology IMMUNOLOGY-

CiteScore

2.20

自引率

0.00%

发文量

154

审稿时长

73 days

期刊介绍： Manuscripts of high standard in the form of original research, multicentric studies, meta analysis, are accepted. Current reports can be submitted as brief communications. Case reports must include review of current literature, clinical details, outcome and follow up. Letters to the editor must be a comment on or pertain to a manuscript already published in the IJMM or in relation to preliminary communication of a larger study. Review articles, Special Articles or Guest Editorials are accepted on invitation.